Q1 EPS Forecast for Theravance Biopharma Raised by Analyst

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Zacks Research boosted their Q1 2027 EPS estimates for shares of Theravance Biopharma in a report issued on Wednesday, April 23rd. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of ($0.40) for the quarter, up from their previous forecast of ($0.41). The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma's FY2027 earnings at ($0.77) EPS.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The business had revenue of $18.75 million during the quarter, compared to analysts' expectations of $29.90 million.

Separately, HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $11.33.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH traded up $0.27 during mid-day trading on Monday, hitting $9.77. 239,693 shares of the company traded hands, compared to its average volume of 280,243. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $10.90. The firm has a market cap of $488.51 million, a P/E ratio of -9.67 and a beta of 0.14. The firm's 50 day simple moving average is $9.10 and its 200 day simple moving average is $9.22.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the company's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 370,038 shares of the company's stock, valued at approximately $3,330,342. This represents a 1.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 6.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds have recently modified their holdings of TBPH. Bank of New York Mellon Corp lifted its holdings in shares of Theravance Biopharma by 1.5% during the first quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company's stock valued at $1,049,000 after purchasing an additional 1,720 shares during the last quarter. Rhumbline Advisers lifted its stake in Theravance Biopharma by 3.8% in the first quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock valued at $556,000 after acquiring an additional 2,293 shares during the last quarter. GAMMA Investing LLC increased its position in Theravance Biopharma by 1,201.8% during the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 3,281 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Theravance Biopharma by 3.7% in the 4th quarter. Wellington Management Group LLP now owns 198,491 shares of the biopharmaceutical company's stock valued at $1,868,000 after acquiring an additional 7,162 shares in the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new position in Theravance Biopharma during the fourth quarter valued at approximately $353,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.